Abstract
We prepared a bone plate enabled with the local, sustained release of
BMP2, which is a drug known to inhibit #Osteoclastic-mediated #boneresorption and also expedite the bone-remodeling activity of
#osteoblasts. For this, we coated a bone plate already in clinical use
(PLT-1031,
Inion, Finland) with a blend of BMP2 and a #biocompatiblepolymer,
4-azidobenzoic acid-modified chitosan (i.e., Az-CH) photo-cross linked
by
#UVirradiation. As we performed the in vitro drug release study, the
drug was released from the coating at an average rate of 4.03μg/day for
63 days in a sustained manner. To examine the effect on #boneregeneration, the plate was fixed on an 8mm cranial critical size defect
in living
rats and the newly formed bone volume was quantitatively evaluated by
micro-computed tomography (micro-CT) at scheduled times over 8
weeks. At week 8, the group implanted with the plate enabled with
sustained delivery of BMP2 showed a significantly higher volume of newly
formed bone (52.78 ± 6.84%) than the groups implanted with the plates
without drug (23.6 ± 3.81%) (p b 0.05). The plate enabled with BMP2
delivery also exhibited good biocompatibility on H&E staining, which
was comparable to the Inion plate already in clinical use. Therefore,
we
suggest that a bone plate enabled with local, sustained delivery of BMP2
can be a promising system with the combined functionality of bone
fixation and its expedited repair.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.